Critical Review: NanoViricides (NYSE:NNVC) and Amarillo Biosciences (OTCMKTS:AMAR)

NanoViricides (NYSE:NNVC) and Amarillo Biosciences (OTCMKTS:AMAR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of recent ratings for NanoViricides and Amarillo Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0	0	1	0	3.00
Amarillo Biosciences	0	0	0	0	0.00

Given Amarillo Biosciences’ higher probable upside, analysts plainly believe Amarillo Biosciences is more favorable than NanoViricides.

Risk & Volatility

NanoViricides has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500.

Earnings & Valuation

This table compares NanoViricides and Amarillo Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29 million	($0.51)	-1.67
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A

Amarillo Biosciences has higher revenue and earnings than NanoViricides.

Institutional and Insider Ownership

10.3% of NanoViricides shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by insiders. Comparatively, 34.4% of Amarillo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares NanoViricides and Amarillo Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Amarillo Biosciences	-41,453.98%	N/A	-574.29%

Summary

NanoViricides beats Amarillo Biosciences on 6 of the 11 factors compared between the two stocks.

About NanoViricides

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.